Insight Molecular Diagnostics (IMDX) Total Current Liabilities (2015 - 2026)

Insight Molecular Diagnostics has reported Total Current Liabilities for 12 years, with the latest figure at $12.0 million in Q1 2026.

• Quarterly Total Current Liabilities rose 23.98% year-over-year to $12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 23.98% YoY) and the FY2025 annual result came in at $12.1 million, up 65.98% from the prior year.
• Total Current Liabilities retreated to $12.0 million in Q1 2026 per IMDX's latest filing, from $12.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $14.2 million in Q2 2022 and troughed at $6.7 million in Q2 2025.
• A 5-year average of $9.7 million and a median of $9.1 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities sank 45.83% in 2023, then surged 65.98% in 2025.
• Over 5 years, Total Current Liabilities stood at $12.1 million in 2022, then slumped by 40.57% to $7.2 million in 2023, then gained by 1.13% to $7.3 million in 2024, then soared by 65.98% to $12.1 million in 2025, then declined by 0.58% to $12.0 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $12.0 million, $12.1 million, and $7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.